参考文献/References:
[1]石远凯,孙燕临床肿瘤内科手册 [M] 第6版 北京:人民卫生出版社 2015: 582
[2]Chene G, Lamblin G, Le Bail-Carval K, et al Early preinvasive lesions in ovarian cancer [J]. Biomed Res Int, 2014 (3): 639252.
[3]Lambert P, Galloway K, Altman A, et al. Ovarian cancer in Manitoba: trends in incidence and survival, 1992-2011 [J]. Curr Oncol, 2017, 24 (2): e78-e84.
[4]Axelson H. Notch signaling and cancer: emerging complexity [J]. Semin Cancer Biol, 2004, 14 (5): 317-319.
[5]LIU Hao, ZHANG Heng, SHEN Zhenbin, et al. Expression of jagged1 predicts postoperative clinical outcome of patients with gastric cancer [J]. Int J Clin Exp Med, 2015, 8(9): 14782-14792.
[6]Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of Colitis-Associated cancer [J]. Cancer Cell, 2009, 15 (2): 103-113.
[7]Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer [J]. Clin Cancer Res, 2011, 17(8): 2538-2548.
[8]Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland [J]. J Clin Invest, 2007, 117(12): 3988-4002.
[9]Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease [J]. Semin Cancer Biol, 2004, 14(5): 320-328.
[10]CHEN Xu, Stoeck A, Lee SJ, et al. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer [J]. Oncotarget, 2010, 1(3): 210-218.
[11]Hsu KW, Hsieh RH, Huang KH, et al. Activation of the notch1/STAT3/twist signaling axis promotes gastric cancer progression[J]. Carcinogenesis, 2012, 33(8): 1459-1467.
[12]Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors [J]. Cell Res, 2008, 18(2): 254-267.
[13]YUAN Jie, YANG Yi, GAO Zicong, et al. Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells [J]. Breast Cancer Res Treat, 2017, 164 (2): 327-340.
[14]ZHANG X, TANG J, ZHI X, et al. Correction:miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT/VEGF-A pathway in gastric cancer[J]. Oncotarget, 2017, 8(17): 29535.
[15]Kim YJ, Kim JY, Lee N, et al. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells [J]. Biochem Biophys Res Commun, 2017, 486 (4): 1069-1076.
[16]Saini U, Naidu S, Elnaggar AC, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target [J]. Oncogene, 2017, 36 (2): 168-181.
相似文献/References:
[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(8):0.
[3]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(8):15.
[4]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(8):59.
[5]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后
患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with
lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(8):72.
[6]石亚利,梁华茂*,姚颖.腹腔镜卵巢恶性肿瘤再分期手术临床分析(附38例报道)[J].中国计划生育和妇产科,2018,(3):37.
SHI Ya-li,LIANG Hua-mao*,YAO Ying.Clinical analysis of laparoscopic restaging surgery for ovarian
malignancies (report of 38 cases)[J].Chinese Journal of Family Planning & Gynecotokology,2018,(8):37.
[7]叶海琼,秦明丽,傅晓冬*.卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估[J].中国计划生育和妇产科,2018,(4):58.
YE Hai-qiong,QIN Ming-li,FU Xiao-dong*.Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(8):58.
[8]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(8):62.
[9]范云龙,杨建华.微生物在卵巢癌发病机制与治疗中的作用[J].中国计划生育和妇产科,2018,(5):24.
[10]吴亚男,李红霞*,孟宪宁,等.子宫内膜异位症及卵巢癌患者血清脑源性神经营养因子水平的表达及意义[J].中国计划生育和妇产科,2018,(9):32.
WU Ya-nan,LI Hong-xia*,MENG Xian-ning,et al.Expression and significance of serum BDNF in patients with endometriosis and ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(8):32.